293
Participants
Start Date
November 25, 2019
Primary Completion Date
August 6, 2024
Study Completion Date
April 7, 2025
Benralizumab 30 mg
"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).~For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE."
Matched placebo
"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
Research Site, Taipei
Research Site, Taipei
Research Site, Taipei
Research Site, Taoyuan District
Research Site, Budapest
Research Site, Budapest
Research Site, Brussels
Research Site, Sofia
Research Site, Sofia
Research Site, Tatabánya
Research Site, Leuven
Research Site, Melbourne
Research Site, Plovdiv
Research Site, Herston
Research Site, Spearwood
Research Site, Kaposvár
Research Site, Székesfehérvár
Research Site, Siófok
Research Site, Ghent
Research Site, Győr
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, The Bronx
Research Site, White Plains
Research Site, Bangkok
Research Site, Taipei
Research Site, Marseille
Research Site, Bethlehem
Research Site, White Marsh
Research Site, Richmond
Research Site, Toulouse
Research Site, Gainesville
Research Site, Bakırköy
Research Site, Izmir
Research Site, Khon Kaen
Research Site, Louisville
Research Site, Malatya
Research Site, Chiang Mai
Research Site, Milwaukee
Research Site, Pisa
Research Site, Phitsanulok
Research Site, Tulsa
Research Site, McKinney
Research Site, Fort Worth
Research Site, Grand Junction
Research Site, St. George
Research Site, Catanzaro
Research Site, Huntington Beach
Research Site, Bellingham
Research Site, Hanoi
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Changchun
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Jinan
Research Site, Yantai
Research Site, Qingdao
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Nanchang
Research Site, Chongqing
Research Site, Changsha
Research Site, Changsha
Research Site, Izhevsk
Research Site, Wuhan
Research Site, Penza
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Foshan
Research Site, Nanning
Research Site, Chengdu
Research Site, Chengdu
Research Site, Ho Chi Minh City
Research Site, Xi'an
Research Site, Xi'an
Research Site, Ürümqi
Research Site, Quillota
Research Site, Talca
Research Site, Santiago
Research Site, Santiago
Research Site, Buenos Aires
Research Site, Buenos Aires
Research Site, Ciudad de Buenos Aire
Research Site, San Fernando
Research Site, Changsha
Research Site, Roma
Research Site, Roma
Research Site, Chiba
Research Site, Fujisawa-shi
Research Site, Hiroshima
Research Site, Ichikawa-shi
Research Site, Iida-shi
Research Site, Kawasaki-shi
Research Site, Kumamoto
Research Site, Meguro-ku
Research Site, Meguro-ku
Research Site, Minatoku
Research Site, Moriguchi-shi
Research Site, Nagaoka-shi
Research Site, Osaka
Research Site, Shinjuku-ku
Research Site, Yoshida-gun
Research Site, Bydgoszcz
Research Site, Elblag
Research Site, Krakow
Research Site, Lublin
Research Site, Nadarzyn
Research Site, Poznan
Research Site, Wroclaw
Research Site, Łodź
Research Site, Aydin
Lead Sponsor
AstraZeneca
INDUSTRY